Improving therapeutic outcomes in the treatment of mild to moderate corona virus disease in COVID 19 positive patients via oral administration of Ayurveda formulations a randomized placebo controlled multicentric study

Ayurved Rasayani0 sites100 target enrollmentTBD

Overview

Phase: 未知
Intervention: Not specified
Conditions: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J101- Influenza due to other identifiedinfluenza virus with other respiratory manifestations
Sponsor: Ayurved Rasayani
Enrollment: 100
Status: Completed
Last Updated: 4 years ago

No summary available.

Registry

who.int

Start Date

TBD

End Date

December 23, 2021

Last Updated

4 years ago

Study Type

Interventional

Sponsor

•1 Age 18 to 60 years
•2 COVID\-19 positive as determined by PCR or other approved commercial or public health assay
•3 Willing and able to provide written informed consent prior to performing study procedures

•1 Participation in any other clinical trial of an experimental treatment for COVID 19
•2 Patients with severe COVID 19 disease defined as follows
•3 Respiratory distress as determined by \>\=30 breaths per min
•oxygen saturation at rest \<\=85%
•Severe disease complications e g respiratory failure requirement of mechanical ventilation, septic shock or non\-respiratory organ failure
•4 Patients with deranged liver functions i.e Total bilirubin \<\= 2 Liver enzymes \<\=2\.5 times Under Normal limits or deranged renal functions i.e Creatinine \<\= 1\.5 times Under Normal limits
•5 Patients with unstable angina or history of Myocardial infarction or underwent CABG
•6 Patients with known diagnosis of COPD
•7 Pregnant women or women who are breastfeeding
•Immunocompromised patients or patients taking immunosuppressant medication or Patients with active malignancy Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive study treatment